Remember what CELG's Scientists Said About Abraxane last month
And that was: Pancreatic cancer is so tough to deal with, getting the "needle to move at all" is a big achievement, whenever you could actually get it to move at all!
PPHM's folks are saying the same thing; so the imrovement IS REAL, albeit "modest", as Menander said.
"We are pleased with the results seen in this very difficult to treat patient population," said Kerstin Menander, MD, PhD, head of medical oncology at Peregrine. "Although the median overall survival improvement is modest, further analysis of the data including subgroups shows some very interesting and potentially promising trends. We look forward to presenting the full data set from this trial later this year at an upcoming scientific meeting."
Let's hope we hear and read about the MORE DETAILED analysis of the double-blind second line NSCLC later this week, too, so PPHM could really get back up to the $500-$700M market cap range...
Cancer is a very broad term, so the "sub-group" analysis --- in terms of what kind of people, with what kind of little gene mutation, etc. who get the MOST out of Bavi --- that is really the *big deal* event, in these high complex diseases.
Scientists are learning each day, you can't really treat everyone with the same molecular drug, to the same level of efficay; you ultimately have to look for the SUB-GROUPS who benefit the most from effective molecules. Other groups will also do the same thing, with their own molecules.
It's truly a part of the "personalized medicine," because we all are so different, at the molecular and DNA levels --- in terms of minute differences/mutations --- no drug can just justice to all who suffer from "breast cancer" or "lung cancer" or "pancreatic cancer," since in each of these "cancers" too there are differences, big and small...